Gilead Sciences Exceeds Expectations
This is a Veklury news story, published by Yahoo Finance, that relates primarily to Gilead Sciences news.
Veklury news
For more Veklury news, you can click here:
more Veklury newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
net earnings. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest year earnings news, financial results news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
adjusted quarterly profitReuters
•Gilead 3rd-quarter results beat Wall Street estimates, raises outlook
75% Informative
Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations.
Third-quarter sales of HIV drug Biktarvy rose 13% to $3.5 billion .
Sales of COVID-19 treatment Veklury rose 9% .
Company raised its product sales forecast to a range of $27.8 billion to $28.1 billion .
VR Score
88
Informative language
98
Neutral language
1
Article tone
formal
Language
English
Language complexity
32
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links